Cannabis Law Report
JULY 31, 2019
billion by 2025, according to a new report by Grand View Research, Inc., Cannabis sales are increasing due to its medical benefits, especially in the treatment of ailments such as chronic pain, mental disorders, and cancer. This is fueling the need for effective pain management programs and treatments for such disorders.
Veriheal
JANUARY 18, 2023
Research commissioned by the Centre for Medicinal Cannabis pinned a £1 billion valuation on the CBD market by the year 2025. This rare type of epilepsy caused her to endure up to 300 grand mal seizures per week from the tender age of five. CBD sales. . About Charlotte’s Web CBD.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JANUARY 12, 2020
It has approved use of cannabis extracts for treatment of a range of illnesses and conditions, including cancer, epilepsy, Alzheimer’s, Parkinson’s disease and anxiety. billion ($96 billion) by the end of 2025. Read more at [link].
Cannabis Law Report
JANUARY 5, 2022
The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. MYMD-1 also shows promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.
Cannabis Law Report
NOVEMBER 16, 2021
Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.
Cannabis Law Report
SEPTEMBER 13, 2021
Commenting on the size and scope of the market for delaying aging, Dr. Chapman added, “There are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 1 according to a major investment bank.
Cannabis Law Report
OCTOBER 20, 2019
It is also the first FDA approved drug for the treatment of patients with Dravet syndrome. billion in federal tax revenue between 2017 and 2025. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.” as a Schedule II substance. Schmidlkofer, M. Westwood, and J. xv] [link].
Expert insights. Personalized for you.
40 
Let's personalize your content